Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

KZIA.US Logo

KZIA.US - Current Price

$6.16

Company Information

▼
Company Name
Kazia Therapeutics Ltd ADR
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US48669G1058
CIK: 0001055886
CUSIP: 67010F103
Currency: USD
Full Time Employees: 6
Phone: 61 2 9472 4101
Website: https://www.kaziatherapeutics.com
Fiscal Year End: June
IPO Date: Jan 06, 1999
Description:

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Address:

Three International Towers, Sydney, NSW, Australia, 2000

Directors & Officers

▼
Name Title Year Born
Dr. John Edwin Friend II, M.D. Chief Executive Officer 1970
Mr. Jeffrey Bonacorda VP of Finance & Controller NA
Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC Company Secretary 1973

Shares Statistics

▼
Shares Outstanding: 11.34M
Shares Float: 904.77M
% Insiders: 138.70%
% Institutions: 174.20%
Short % Float: 0.36%

Valuation Metrics

▼
Enterprise Value: $74.67M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $73.00M
EBITDA: $-13.28M
Book Value: $-3.43
Earnings/Share: $-12.64
Profit Margin: 0.00%
Operating Margin: -268.37%
ROA (TTM): -64.28%
ROE (TTM): -3,891.64%
Revenue (TTM): $1.83M
Revenue/Share (TTM): $1.67
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -27.20%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Mar 31, 2025 -12.30 0.00 N/A N/A
Sep 30, 2024 -31.22 0.00 N/A N/A
Mar 31, 2021 -0.01 0.00 N/A N/A
Dec 31, 2020 -0.01 0.00 N/A N/A
Sep 30, 2020 -0.02 0.00 N/A N/A
Jun 30, 2020 -0.02 0.00 N/A N/A
Mar 31, 2020 -0.03 0.00 N/A N/A
Dec 31, 2019 -0.03 0.00 N/A N/A
Sep 30, 2019 -0.03 0.00 N/A N/A
Jun 30, 2019 -0.03 0.00 N/A N/A
Mar 31, 2019 -0.02 0.00 N/A N/A
Dec 31, 2018 -0.02 0.00 N/A N/A
Sep 30, 2018 -0.04 0.00 N/A N/A
Jun 30, 2018 -0.04 0.00 N/A N/A
Mar 31, 2018 -0.05 0.00 N/A N/A
Dec 31, 2017 0.01 0.00 N/A N/A
Sep 30, 2017 0.00 0.00 N/A N/A
Jun 30, 2017 -0.13 0.00 N/A N/A
Mar 31, 2017 -0.05 0.00 N/A N/A
Dec 31, 2016 -0.09 0.00 N/A N/A
Sep 30, 2016 -0.19 0.00 N/A N/A
Jun 30, 2016 -0.04 0.00 N/A N/A
Mar 31, 2016 -0.07 0.00 N/A N/A
Dec 31, 2015 -0.09 0.00 N/A N/A
Sep 30, 2015 -0.03 0.00 N/A N/A
Jun 30, 2015 -0.03 0.00 N/A N/A
Mar 31, 2015 -0.06 0.00 N/A N/A
Dec 31, 2014 -0.06 0.00 N/A N/A
Sep 30, 2014 -0.05 0.00 N/A N/A
Jun 30, 2014 -0.06 0.00 N/A N/A
Mar 31, 2014 -0.12 0.00 N/A N/A
Dec 31, 2013 -0.12 0.00 N/A N/A
Sep 30, 2013 -0.09 0.00 N/A N/A
Jun 30, 2013 -0.10 0.00 N/A N/A
Sep 30, 2012 -0.01 0.00 N/A N/A
Jun 30, 2012 -0.01 0.00 N/A N/A
Mar 31, 2012 0.04 0.00 N/A N/A
Dec 31, 2011 0.04 0.00 N/A N/A
Sep 30, 2011 0.02 0.00 N/A N/A
Jun 30, 2011 0.02 0.00 N/A N/A
Mar 31, 2011 -0.08 0.00 N/A N/A
Dec 31, 2010 -0.08 0.00 N/A N/A
Sep 30, 2010 -0.32 0.00 N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2025-06-30 $4.35M $N/A $6.06M $14.36M $-8.30M
2024-06-30 $1.66M $N/A $21.59M $31.60M $-10.02M
2023-06-30 $5.24M $N/A $28.08M $16.03M $12.05M
2022-06-30 $7.36M $N/A $35.89M $17.61M $18.28M
2021-06-30 $27.59M $N/A $58.09M $20.24M $37.85M
2020-06-30 $8.76M $N/A $23.06M $8.94M $14.13M
2019-06-30 $5.43M $N/A $21.18M $7.01M $14.20M
2018-06-30 $5.96M $N/A $28.18M $8.93M $19.24M
2017-06-30 $14.45M $N/A $35.91M $10.57M $25.34M
2016-06-30 $33.45M $N/A $35.52M $1.59M $33.93M
2015-06-30 $44.37M $N/A $46.14M $1.78M $44.67M
2014-06-30 $2.50M $N/A $4.66M $3.25M $1.51M
2013-06-30 $8.35M $N/A $8.99M $3.87M $3.48M
2012-06-30 $8.35M $N/A $8.99M $3.87M $3.48M
2011-06-30 $6.02M $N/A $12.73M $8.31M $4.23M
2010-06-30 $15.13M $N/A $19.29M $6.11M $11.19M
2009-06-30 $33.34M $N/A $37.84M $9.07M $23.68M
2008-06-30 $27.99M $N/A $43.38M $7.76M $30.67M
2007-06-30 $39.55M $N/A $51.42M $6.74M $40.62M
2006-06-30 $24.40M $N/A $51.11M $6.52M $42.46M
2005-06-30 $47.07M $N/A $67.21M $6.97M $56.52M
2004-06-30 $58.08M $N/A $76.94M $29.12M $44.81M
2003-06-30 $30.91M $N/A $50.62M $8.38M $41.67M
2002-06-30 $39.96M $N/A $61.93M $7.86M $53.31M
2001-06-30 $61.00M $N/A $119.94M $18.22M $101.72M
2000-06-30 $28.82M $N/A $65.02M $12.29M $52.73M
1999-06-30 $29.51M $N/A $55.88M $8.39M $47.49M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 20, 2023 N/A N/A N/A N/A N/A N/A
Mar 13, 2023 N/A N/A N/A N/A N/A N/A
Mar 03, 2023 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist